# A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

> **NCT06136559** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1200 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Nemtabrutinib
- **DRUG:** Ibrutinib
- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT06136559
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-13
- **Primary completion:** 2032-09-07
- **Final completion:** 2032-09-07
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06136559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06136559, "A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06136559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*